Literature DB >> 1982718

Oral candidosis in HIV-infected patients. Prognostic value and correlation with immunological parameters.

A Plettenberg1, E Reisinger, U Lenzner, H Listemann, M Ernst, P Kern, M Dietrich, W Meigel.   

Abstract

In a prospective study, 29 patients were observed over a period of 42 weeks for signs of oral candidosis (OC), immunological parameters and other typical AIDS-related events. Before the study started, no OC was observed in any of the patients. During the observation period, OC was diagnosed in 12 of the 29 patients (41%). 5 of these 12 patients (42%) developed full-blown AIDS during the 42 weeks. In contrast, a progression to AIDS was observed in only 1 of the 17 patients (5.9%) without OC. The laboratory findings for patients with and without OC showed statistically significant differences for neopterin (23.6 against 14.4 nmol l-1), CD4 counts (417 against 763/mm3) and CD4/CD8 ratios (0.45 against 0.85). Based on these results, it seems justifiable to consider prophylactic measures such as pentamidine inhalation and/or treatment with zidovudine in HIV-infected patients with immunodeficiency and occurrence of OC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982718     DOI: 10.1111/myc.1990.33.9-10.421

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

1.  Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  J L Lopez-Ribot; R K McAtee; S Perea; W R Kirkpatrick; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Fluconazole therapy of oral candidiasis in HIV-infected patients: results of a multicentre study.

Authors:  A Plettenberg; A Stoehr; G Höffken; C Bergs; B Tschechne; M Ruhnke; W Heise; S Dieckmann; W Meigel
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.